STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks. U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.
- ▪You can reach Andrew confidentially on Signal at drewqjoseph.71.
- ▪LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
- ▪U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.
STAT News files mainly under health. We currently carry 235 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT News |
| Canonical URL | https://www.statnews.com/2026/06/30/abivax-obefazimod-ulcerative-colitis-maintenance-trial-safety-data/?utm_campaign=rss |
| Publication time | Tue, 30 Jun 2026 07:05:22 +0000 |
| Retrieval time | 2026-06-30T07:24:23.532Z |
| Last seen | 2026-06-30T07:24:23.532Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 4nank1wGUyD_ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
STAT PlusBiotech Abivax seeks to ease safety concerns with new data, boosting shares The company released additional strong efficacy results, in a group of hard-to-treat patients Manage alerts for this article Email this article Share this article A micrograph of ulcerative colitis.Wikimedia Commons By Andrew JosephJune 30, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT News.
Discussion
0 commentsMore from STAT News
